Intracranial Delivery of B7-H3-Targeting CAR-T Cells for Recurrent Glioblastoma: A Phase 1 Trial

CAR-T Lentiviral Particles: Revolutionizing Cancer Immunotherapy

CAR-T cell therapy has emerged as a groundbreaking approach in the fight against cancer, particularly for hematologic malignancies.

Stress-sensing cells hold promise as glioblastoma treatment

Treatments using gamma delta T-cells, a type of immune cell, hold promise for treating glioblastoma, scientists said, though they added that much more research is needed to determine whether these therapies are safe and effective in people with the disease. They laid out the promises and hurdles of developing the treatments in a paper, “Challenges and Opportunities of γδ T Cell-Based Immunotherapy for Glioblastoma,” published in Biomedicines. Th…

SL Science co-authors Biomedicines article on γδ T Cell Therapy in Glioblastoma - BioTuesdays

SL Science Holding (NASDAQ: SLBT) has announced the publication of a peer-reviewed article in Biomedicines co-authored by SL Science leadership and

Intracranial Delivery of B7-H3-Targeting CAR-T Cells for Recurrent Glioblastoma: A Phase 1 Trial

Scientists presented the complete results of a Phase I trial investigating the safety and efficacy of autologous B7-H3-targeting chimeric antigen receptor T cell therapy for the treatment of recurrent glioblastoma. [Nature Medicine] Abstract